OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. McKay on the Real-World Utilization of Radium-223 in mCRPC

March 13th 2020

Rana R. McKay, MD, discusses results from an analysis examining the real-world utilization of radium-223 (Xofigo) in metastatic castration-resistant prostate cancer.

Dr. Chao on the Utility of MSI as a Biomarker in Gastric/GEJ Cancer

March 12th 2020

Joseph Chao, MD, discusses the utility of microsatellite instability (MSI) status as a prognostic biomarker in gastric and gastroesophageal cancer.

Dr. Huey on Sequencing Sorafenib Among Novel Combos in HCC

March 12th 2020

Ryan W. Huey, MD, discusses potential sequencing options with sorafenib among novel combination strategies in hepatocellular carcinoma.

Dr. Gonzalez-Martin on the PRIMA Trial Design in Ovarian Cancer

March 12th 2020

Antonio González-Martín, MD, discusses the design of the PRIMA trial in ovarian cancer.

Dr. Choueiri on Safety Profile of MK-6482 in Advanced Clear Cell RCC

March 12th 2020

Toni K. Choueiri, MD, discusses the safety profile of the oral HIF-2α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma.

Dr. Coleman on Results of the VELIA Trial in Ovarian Cancer

March 12th 2020

Robert L. Coleman, MD, FACOG, FACS, discusses the results of the phase III VELIA trial examining veliparib in combination with chemotherapy in ovarian cancer.

Dr. Finn on Biomarkers of Response in HCC

March 12th 2020

Richard S. Finn, MD, discusses biomarkers of response to immunotherapy in hepatocellular carcinoma.

Dr. Iyer on Erdafitinib-Related Hyperphosphatemia in Metastatic Urothelial Cancer

March 12th 2020

Gopa Iyer, MD, discusses treatment-emergent hyperphosphatemia with erdafitinib in patients with metastatic urothelial cancer.

Dr. Kaseb on the Progression of HCC Research

March 12th 2020

Ahmed O. Kaseb, MD, discusses the progression of therapy options for patients with hepatocellular carcinoma.

Dr. Oh on Design and Results of the PRINT Trial in Castration-Resistant Prostate Cancer

March 12th 2020

William K. Oh, MD, discusses the design and findings of the PRINT trial in metastatic castration-resistant prostate cancer.

Dr. Gould on the Implications of the NELSON Trial in Lung Cancer

March 11th 2020

Michael K. Gould, MD, MS, pulmonologist and director of the Division of Health Services Research and Implementation Science at Kaiser Permanente Southern California, discusses the implications of the NELSON trial in lung cancer.

Dr. Nelson on the Benefit of Primary Tumor Resection in mCRC

March 11th 2020

Douglas A. Nelson, MD, associate professor in the Department of General Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the benefit of primary tumor resection in patients with metastatic colorectal cancer (mCRC).

Dr. Tolaney on Navigating Adjuvant Therapy in Early-Stage HER2+ Breast Cancer

March 11th 2020

Sara M. Tolaney, MD, MPH, associate director, Susan F. Smith’s Center for Women’s Cancers, director, Clinical Trials, Breast Oncology, senior physician, Dana-Farber Cancer Institute, and assistant professor of medicine at Harvard Medical School, discusses considerations for adjuvant therapy in patients with early-stage HER2-positive breast cancer.

Dr. Coleman on the VELIA Trial Impact on Ovarian Cancer Practice

March 11th 2020

Robert L. Coleman, MD, FACOG, FACS, discusses the impact of the VELIA trial on ovarian cancer practice.

Dr. Musher on Current Therapies for HCC

March 11th 2020

Benjamin Leon Musher, MD, discusses the current treatment options for patients with hepatocellular carcinoma.

Dr. Overman on Investigational Targeted Therapies in mCRC

March 11th 2020

Michael J. Overman, MD, professor in the Department of Gastrointestinal Medical Oncology of the Division of Cancer Medicine and committee vice chair at The University of Texas MD Anderson Cancer Center, discusses investigational targeted therapies in metastatic colorectal cancer (mCRC).

Dr. Abdul-Hay on the Use of BiTEs in ALL

March 11th 2020

Mohammad Maher Abdul-Hay, MD, an assistant professor in the Department of Medicine; director of the Clinical Leukemia Program in NYU Langone Health’s Perlmutter Cancer Center; and associate director for research in the Bellevue Cancer Center, discusses the use of bispecific T-cell engagers (BiTEs) in acute lymphoblastic leukemia (ALL).

Dr. Dimou on Limitations of TMB as a Biomarker in Lung Cancer

March 11th 2020

Anastasios (Tassos) Dimou, MD, discusses the limitations of tumor mutational burden as a biomarker in lung cancer.

Dr. Rugo on the Utility of Margetuximab in HER2+ Metastatic Breast Cancer

March 11th 2020

Hope S. Rugo, MD, discusses the utility of margetuximab in HER2-positive metastatic breast cancer.

Dr. Villa on Retrospective Data of Bendamustine/Rituximab in MCL

March 10th 2020

Diego Villa, MD, MPH, discusses the findings of a retrospective analysis looking at bendamustine plus rituximab in mantle cell lymphoma.